Arthur N Westover1, Paul A Nakonezny2, Carolyn E Barlow3, Wanpen Vongpatanasin4, Bryon Adinoff5, E Sherwood Brown6, Eric M Mortensen7, Ethan A Halm8, Laura F DeFina3. 1. Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of Clinical Sciences, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. Electronic address: arthur.westover@utsouthwestern.edu. 2. Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of Clinical Sciences, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. 3. The Cooper Institute, Dallas, TX, USA. 4. Hypertension Section, Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. 5. Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; VA North Texas Health Care System, Dallas VAMC, 4500 South Lancaster Road, Dallas, TX 75216, USA. 6. Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. 7. VA North Texas Health Care System, Dallas VAMC, 4500 South Lancaster Road, Dallas, TX 75216, USA; Division of General Internal Medicine, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. 8. Division of General Internal Medicine, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Abstract
BACKGROUND: To compare users of stimulant medications with matched nonusers on exercise outcomes during a maximal treadmill exercise test. METHODS: A cross-sectional study of a community-based cohort comparing propensity-score-matched stimulant medication users (n = 245) and nonusers (n = 735) who underwent a maximal treadmill exercise test in the Cooper Center Longitudinal Study cohort from January 1, 1995 to December 31, 2013. Main Outcomes were peak systolic blood pressure (SBP), average rise in SBP, peak heart rate (HR), and estimated VO2max during exercise. A linear mixed model analysis was used to evaluate the effect of stimulant exposure on each of the exercise outcomes. In a sensitivity analysis, users were compared against nonusers for risk of chronotropic incompetence. Analyses were adjusted for relevant covariates and multiple testing. RESULTS: Peak HR during exercise was significantly lower in stimulant medication users (least square mean estimate 170.2 beats/minute) compared to nonusers (174.4 beats/minute; p < 0.0001). Moreover, stimulant medication users had an increased risk of chronotropic incompetence compared to nonusers (adjusted odds ratio 3.28, 95% confidence interval 1.70 to 6.34, p = 0.0008). No significant differences were observed in the outcomes of peak SBP, average SBP rise, and estimated VO2max between matched groups. CONCLUSIONS: Stimulant medication use was associated with a significant decrease in peak HR and an increased risk of chronotropic incompetence. Further investigation is required to understand the clinical significance of chronotropic incompetence in stimulant medication users. Concerns that stimulant medication use may increase peak SBP and average SBP during exercise were not supported by this study.
BACKGROUND: To compare users of stimulant medications with matched nonusers on exercise outcomes during a maximal treadmill exercise test. METHODS: A cross-sectional study of a community-based cohort comparing propensity-score-matched stimulant medication users (n = 245) and nonusers (n = 735) who underwent a maximal treadmill exercise test in the Cooper Center Longitudinal Study cohort from January 1, 1995 to December 31, 2013. Main Outcomes were peak systolic blood pressure (SBP), average rise in SBP, peak heart rate (HR), and estimated VO2max during exercise. A linear mixed model analysis was used to evaluate the effect of stimulant exposure on each of the exercise outcomes. In a sensitivity analysis, users were compared against nonusers for risk of chronotropic incompetence. Analyses were adjusted for relevant covariates and multiple testing. RESULTS: Peak HR during exercise was significantly lower in stimulant medication users (least square mean estimate 170.2 beats/minute) compared to nonusers (174.4 beats/minute; p < 0.0001). Moreover, stimulant medication users had an increased risk of chronotropic incompetence compared to nonusers (adjusted odds ratio 3.28, 95% confidence interval 1.70 to 6.34, p = 0.0008). No significant differences were observed in the outcomes of peak SBP, average SBP rise, and estimated VO2max between matched groups. CONCLUSIONS: Stimulant medication use was associated with a significant decrease in peak HR and an increased risk of chronotropic incompetence. Further investigation is required to understand the clinical significance of chronotropic incompetence in stimulant medication users. Concerns that stimulant medication use may increase peak SBP and average SBP during exercise were not supported by this study.
Authors: Babak Azarbal; Sean W Hayes; Howard C Lewin; Rory Hachamovitch; Ishac Cohen; Daniel S Berman Journal: J Am Coll Cardiol Date: 2004-07-21 Impact factor: 24.094
Authors: Sharon B Wigal; Dan Nemet; James M Swanson; Roland Regino; Joey Trampush; Michael G Ziegler; Dan M Cooper Journal: Pediatr Res Date: 2003-03-05 Impact factor: 3.756
Authors: Nora D Volkow; Gene-Jack Wang; Joanna S Fowler; Patricia E Molina; Jean Logan; S John Gatley; Andrew Gifford; Yu-Shin Ding; Christopher Wong; Naomi R Pappas; Wei Zhu; James M Swanson Journal: Psychopharmacology (Berl) Date: 2003-02-13 Impact factor: 4.530
Authors: J N Cohn; T B Levine; M T Olivari; V Garberg; D Lura; G S Francis; A B Simon; T Rector Journal: N Engl J Med Date: 1984-09-27 Impact factor: 91.245
Authors: Mercedes R Carnethon; Samuel S Gidding; Rodrigo Nehgme; Stephen Sidney; David R Jacobs; Kiang Liu Journal: JAMA Date: 2003-12-17 Impact factor: 56.272
Authors: Arthur N Westover; Paul A Nakonezny; Bryon Adinoff; Edson Sherwood Brown; Ethan A Halm Journal: J Child Adolesc Psychopharmacol Date: 2016-09-14 Impact factor: 2.576
Authors: Arthur N Westover; Paul A Nakonezny; Carolyn E Barlow; Bryon Adinoff; E Sherwood Brown; Ethan A Halm; Wanpen Vongpatanasin; Laura F DeFina Journal: J Clin Psychopharmacol Date: 2016-06 Impact factor: 3.153
Authors: Helmut K Lackner; Manfred G Moertl; Karin Schmid-Zalaudek; Miha Lucovnik; Elisabeth M Weiss; Vassiliki Kolovetsiou-Kreiner; Ilona Papousek Journal: Front Physiol Date: 2018-09-03 Impact factor: 4.566
Authors: Anna Hirschbeck; Douglas Silva Leao; Elias Wagner; Alkomiet Hasan; Astrid Roeh Journal: Front Psychiatry Date: 2022-09-06 Impact factor: 5.435